Artículos por temáticas

APP transgenic mice and their application to drug discovery

Howlett DR.

Histol Histopathol. 2011 Dec;26(12):1611-32. doi: 10.14670/HH-26.1611.

The beneficial role of vitamin D in Alzheimer's disease

Lu'o'ng KV, Nguyên LT.

Am J Alzheimers Dis Other Demen. 2011 Nov;26(7):511-20. doi: 10.1177/1533317511429321. Epub 2011 Dec 27.

Aggregation state and neurotoxic properties of alzheimer β-amyloid peptide

Mohamed A, Cortez L, de Chaves EP.

Curr Protein Pept Sci. 2011 May;12(3):235-57. doi: 10.2174/138920311795860214.

Toward a unifying hypothesis in the development of Alzheimer's disease

Balin B, Abrams JT, Schrogie J.

CNS Neurosci Ther. 2011 Dec;17(6):587-9. doi: 10.1111/j.1755-5949.2011.00269.x.

Mitophagy in neurodegeneration: an opportunity for therapy?

Santos RX, Correia SC, Carvalho C, Cardoso S, Santos MS, Moreira PI.

Curr Drug Targets. 2011 Jun;12(6):790-9. doi: 10.2174/138945011795528813.

Galantamine and behavior in Alzheimer disease: analysis of four trials

Kavanagh S, Gaudig M, Van Baelen B, Adami M, Delgado A, Guzman C, Jedenius E, Schäuble B.

Acta Neurol Scand. 2011 Nov;124(5):302-8. doi: 10.1111/j.1600-0404.2011.01525.x. Epub 2011 May 26.

Sublingual sufentanil for incident pain and dementia-related response agitation

Passmore MJ.

Int Psychogeriatr. 2011 Jun;23(5):844-6. doi: 10.1017/S1041610211000275. Epub 2011 Feb 25.

γ-secretase substrates and their implications for drug development in Alzheimer's disease

Lleó A, Saura CA.

Curr Top Med Chem. 2011;11(12):1513-27. doi: 10.2174/156802611795861004.

Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly

Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E, Ricevuti G.

Autoimmun Rev. 2011 Dec;11(2):149-53. doi: 10.1016/j.autrev.2011.09.005. Epub 2011 Oct 5.

Current and emerging drug treatment options for Alzheimer's disease: a systematic review

Herrmann N, Chau SA, Kircanski I, Lanctôt KL.

Drugs. 2011 Oct 22;71(15):2031-65. doi: 10.2165/11595870-000000000-00000.

[New conception of Alzheimer's disease and the strategy for preclinical therapy]

Miyagawa T, Iwata A.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:252-6.

A clinical perspective: anti tau's treatment in Alzheimer's disease

Fuentes P, Catalan J.

Curr Alzheimer Res. 2011 Sep;8(6):686-8. doi: 10.2174/156720511796717221.

In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease

Yokokura M, Mori N, Yagi S, Yoshikawa E, Kikuchi M, Yoshihara Y, Wakuda T, Sugihara G, Takebayashi K, Suda S, Iwata Y, Ueki T, Tsuchiya KJ, Suzuki K, Nakamura K, Ouchi Y.

Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):343-51. doi: 10.1007/s00259-010-1612-0. Epub 2010 Sep 16.

Prescription of lipophilic statins to Alzheimer's disease patients: some controversies to consider

Biondi E.

Neurol Sci. 2011 Apr;32(2):195-201. doi: 10.1007/s10072-010-0440-0. Epub 2010 Oct 19.

Biomarkers for Alzheimer's disease therapeutic trials

Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vella

Prog Neurobiol. 2011 Dec;95(4):579-93. doi: 10.1016/j.pneurobio.2010.11.005. Epub 2010 Dec 2.